PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is $-0.13, expectations were $-0.2.

A new Kentucky law could shield agrochemical maker Bayer from lawsuits claiming it failed to warn that Roundup weedkiller ...

Merck (MRK) stock is in focus as the EU approves its anti-PD-1 therapy, Keytruda, with chemotherapy for certain adults with ...

Swim Across America will host the 5th annual Swim Across America-Florida Keys open water swim on Saturday, April 18, 2026, at ...

Lindsay Curtis is a health & medical writer in South Florida. She worked as a communications professional for health nonprofits and the University of Toronto’s Faculty of Medicine and Faculty of ...

The European approval is based on results from the Phase III KEYNOTE-B96 trial, which also supported the regimen's approval in the US.